Current approaches to the management of brain metastases
JH Suh, R Kotecha, ST Chao, MS Ahluwalia… - Nature reviews Clinical …, 2020 - nature.com
Brain metastases are a very common manifestation of cancer that have historically been
approached as a single disease entity given the uniform association with poor clinical …
approached as a single disease entity given the uniform association with poor clinical …
Single-and multifraction stereotactic radiosurgery dose/volume tolerances of the brain
Purpose As part of the American Association of Physicists in Medicine Working Group on
Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) …
Stereotactic Body Radiotherapy investigating normal tissue complication probability (NTCP) …
[HTML][HTML] Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
R Bartsch, AS Berghoff, J Furtner, M Marhold… - Nature medicine, 2022 - nature.com
Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in
human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We …
human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We …
[HTML][HTML] EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
E Le Rhun, M Guckenberger, M Smits, R Dummer… - Annals of …, 2021 - Elsevier
Highlights•This Clinical Practice Guideline provides management recommendations for
patients with brain metastases from solid tumours.•The guideline covers clinical and …
patients with brain metastases from solid tumours.•The guideline covers clinical and …
Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open …
HA Tawbi, PA Forsyth, FS Hodi, AP Algazi… - The lancet …, 2021 - thelancet.com
Background Combination nivolumab plus ipilimumab was efficacious in patients with
asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low …
asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low …
Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single …
M Yan, Q Ouyang, T Sun, L Niu, J Yang, L Li… - The Lancet …, 2022 - thelancet.com
Background Patients with HER2-positive metastatic breast cancer have a high risk of
developing brain metastases. Efficacious treatment options are scarce. We investigated the …
developing brain metastases. Efficacious treatment options are scarce. We investigated the …
Brain metastases
AS Achrol, RC Rennert, C Anders, R Soffietti… - Nature Reviews …, 2019 - nature.com
An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …
[HTML][HTML] TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain …
RA Freedman, RS Gelman, CK Anders… - Journal of Clinical …, 2019 - ncbi.nlm.nih.gov
PURPOSE Evidence-based treatments for metastatic, human epidermal growth factor
receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported …
receptor 2 (HER2)–positive breast cancer to the CNS are limited. We previously reported …
Brain metastasis
Brain metastasis, which commonly arises in patients with lung cancer, breast cancer and
melanoma, is associated with poor survival outcomes and poses distinct clinical challenges …
melanoma, is associated with poor survival outcomes and poses distinct clinical challenges …
[HTML][HTML] Selective RET kinase inhibition for patients with RET-altered cancers
Background Alterations involving the RET kinase are implicated in the pathogenesis of lung,
thyroid and other cancers. However, the clinical activity of multikinase inhibitors (MKIs) with …
thyroid and other cancers. However, the clinical activity of multikinase inhibitors (MKIs) with …